Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jin Seok Ahn
Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
JAMA Oncology
Cancer Research
Oncology
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and Its Clinical Implication
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient With IHC-Positive and FISH-Negative ALK
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-mutated Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Permanent Chemotherapy‐Induced Alopecia in Patients With Breast Cancer: A 3‐Year Prospective Cohort Study
Oncologist
Cancer Research
Medicine
Oncology
Pazopanib Maintenance After First-Line Etoposide and Platinum Chemotherapy in Patients With Extensive Disease Small-Cell Lung Cancer: A Multicentre, Randomised, Placebo-Controlled Phase II Study (KCSG-LU12-07)
British Journal of Cancer
Cancer Research
Oncology
A Phase II Trial of the Pan-Her Inhibitor Poziotinib, in Patients With HER2-positive Metastatic Breast Cancer Who Had Received at Least Two Prior HER2-directed Regimens: Results of the NOV120101-203 Trial
International Journal of Cancer
Cancer Research
Oncology
Molecular Characterization of Patients With Pathologic Complete Response or Early Failure After Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer Using Next Generation Sequencing and nCounter Assay
Oncotarget
Oncology
Clinical Implications of Genomic Profiles in Metastatic Breast Cancer With a Focus on TP53 and PIK3CA, the Most Frequently Mutated Genes
Oncotarget
Oncology
1
2
›